[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550705":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":33,"responsibleParty":50,"collaborators":19,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":19,"enrollmentInfo":62,"targetDuration":19,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":35,"whyStopped":19,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Centre Henri Becquerel","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Dynamic and static acquisition","EXPERIMENTAL","Dynamic and static PET acquisitions with 18F-FDG and 68Ga-PSMA will be performed with a minimum of 24 hours and a maximum of 15 days between the two",[13],"Other: Parametric acquisition",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Parametric acquisition","Parametric acquisition for 18F-FDG PET\u002FCT and 68GA-PSMA PET\u002FCT with 24 h at 15 days of interval",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Pierre Decazes, MD,PhD","STUDY_DIRECTOR",[25,29],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","+3276673059","pierre.decazes@chb.unicancer.fr",{"name":30,"role":26,"phone":31,"phoneExt":19,"email":32},"Doriane Richard, PhD","+3232082985","doriane.richard@chb-unicancer.fr",[34],{"facility":5,"status":35,"city":36,"state":19,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Rouen","76000","France","FR",{"type":41,"coordinates":42},"Point",[43,44],1.09932,49.44313,{"lat":44,"lon":43},[47],{"name":48,"role":26,"phone":49,"phoneExt":19,"email":28},"Pierre Decazes, Md","+3376673059",{"type":51,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100550705","dynamic-68ga-psma-and-18f-fdg-petct-analysis-prior-to-177lu-psma-100550705",false,"NCT06450548","Dynamic 68Ga-PSMA and 18F-FDG PET\u002FCT Analysis Prior to 177Lu-PSMA","Dynamic 68Ga-PSMA and 18F-FDG PET\u002FCT Analysis of Metastatic Prostatic Adenocarcinomas Prior to 177Lu-PSMA Treatment","PYPET","Inclusion Criteria:\n\n* Signed informed consent.\n* Progressive metastatic castration-resistant prostate adenocarcinoma, which has been treated with taxane chemotherapy and at least one anti-androgen hormone therapy.\n* Evaluated by 18F-FDG and 68Ga-PSMA PET\u002FCT prior to potential treatment with 177Lu-PSMA.\n* Affiliated with or beneficiary of a social protection scheme.\n* WHO stage 0 or 1.\n\nExclusion Criteria:\n\n* Patients unable to understand the study for any reason or comply with the trial requirements (due to language barriers, psychological issues, geographical constraints, etc.).\n* Patients unable to undergo the examinations and\u002For maintain a prolonged lying position (due to back pain, etc.).","MALE","18 Years",{"count":63,"type":64},60,"ESTIMATED","INTERVENTIONAL",[67],"NA","Prostate cancer is a significant health issue, representing 21.8% of male cancer cases in France with over 449,000 new cases in 2018. It's the cause of 10% of cancer deaths in Europe.\n\nThe PSMA is a target for mCRPC treatment, with therapies like 177Lu-PSMA-617 delivering radiation to cancer cells. The Vision study showed that 177Lu-PSMA-617, combined with standard care, improved survival rates significantly compared to standard care alone.The French ANSM authorized 177Lu-PSMA-617 for mCRPC under certain conditions. Patients must have histologically confirmed mCRPC, be progressive despite treatment, and have PSMA-positive imaging.\n\nImaging assessments include PSMA PET\u002FCT and 18F-FDG PET\u002FCT to identify FDG-positive and PSMA-negative sites, which are associated with a poorer prognosis.\n\nParametric analysis using dynamic PET could improve lesion characterization, aiding in treatment decisions. This is the focus of the PyPET study.\n\nThe main objective focuses on a comparative analysis of data from dynamic parametric analysis (metabolic influx rate Ki, volume of distribution Vd) and static analysis (standard at 1 hour) using 18F-FDG and 68Ga-PSMA PET\u002FCT for diagnosing metastases, especially in the liver, lymph nodes, and bones. It aims to assess the effectiveness of these imaging techniques in accurately identifying metastatic sites.",[70],"Prostate Cancer Metastatic",[72,73,74],"prostate cancer","68GA-PSMA","parametric acquisition","2025-12-29",{"date":77,"type":78},"2026-01-02","ACTUAL",{"date":80,"type":78},"2025-03-05",{"date":82,"type":64},"2028-03-05",{"name":5,"class":6},1]